Tyk2-mediated signal transduction lies at the crossroads of multiple pathogenic cytokines, and its specific inhibition may provide effective treatment with comorbid IMIDs, such as psoriasis, psoriatic arthritis, spondyloarthropathies, and inflammatory bowel disease. Here, TYK2 is linked to psoriatic arthritis.